APE prevents NAFLD progression, potentially by regulating gut microbiota, protecting the intestinal mucosal barrier, and inhibiting the LPS/TLR4/MyD88/NF-κB pathway. The gene discussed is MYD88; the disease is metabolic dysfunction-associated steatotic liver disease.